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Novelty and impact 
Breast cancer is not a HIV-associated malignancy, but it occurs among women with as well as among 
women without HIV. Here we provide the first global and regional estimates of incident breast cancer 
in women with HIV.  In 2012, more than 6000 women with HIV, most of them premenopausal women 
in sub-Saharan African, were diagnosed with breast cancer. Research into barriers to early diagnosis, 
care and outcomes is needed for this growing HIV-positive population.  
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Abstract 
There is a growing population of older women living with HIV/AIDS (WLWHA). Breast cancer is a 
common cancer in women worldwide, but the global number of breast cancers in WLWHA is not 
known. We estimated, for each UN sub-region, the number and age distribution of WLWHA who 
were diagnosed with breast cancer in 2012, by combining IARC-GLOBOCAN estimates of age-
country specific breast cancer incidence with corresponding UNAIDS HIV prevalence. Primary 
analyses assumed no HIV-breast cancer association, and a breast cancer risk reduction scenario was 
also considered.  Amongst 16.0 million WLWHA aged 15+ years, an estimated 6325 WLWHA were 
diagnosed with breast cancer in 2012, 74% of whom were in sub-Saharan Africa, equally distributed 
between Eastern, Southern and Western Africa. In most areas, 70% of HIV-positive breast cancers 
were diagnosed under age 50. Among all breast cancers (regardless of HIV status), HIV-positive 
women constituted <1% of the clinical burden, except in Eastern, Western and Middle Africa where 
they comprised 4 to 6% of under age 50 year old breast cancer patients, and in Southern Africa where 
this patient subgroup constituted 26% and 8% of breast cancers diagnosed under and over age 50 
respectively. If a deficit of breast cancer occurs in WLWHA, the global estimate would reduce to 
3600. In conclusion, worldwide, the number of HIV-positive women diagnosed with breast cancer was 
already substantial in 2012 and with an expected increase within the next decade, early detection and 
treatment research targeted to this population are needed. 
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Introduction 
The evolution of the HIV epidemic, in particular with expansion of access to antiretroviral therapy, has 
resulted in an increase in the number of people living with HIV or AIDS (PLWHA) in middle and old 
age. Over age 50, this population has doubled since 1995 and, in 2013,  UNAIDS estimated that it was 
between 4.0 and 4.5 of the 35 million PLWHA.
1
 At these older ages, the risks and management of 
non-communicable diseases become increasingly relevant2, including of cancers that are neither 
AIDS-defining nor HIV-associated. The latter cancers now constitute the majority of cancers in 
PLWHA in more developed settings,2 which has spurred their epidemiologic and clinical research.3  
 
A common malignancy worldwide, regardless of HIV prevalence, is breast cancer. Notably, this 
malignancy is the first or second most common cancer in women in all but 9 countries worldwide 
(Figure 1), including in the sub-regions of Southern, Eastern and Western Africa where 60% of 
women living with HIV or AIDS (WLWHA) aged over 50 years reside.   
 
Several studies have documented breast cancer in WLWHA. These studies predominantly originated 
from North America and Europe,4,5 especially since the widespread uptake of antiretroviral therapy 
(HAART). Notably, between 1991-95 and 2001-05, there was a ten-fold increase in the absolute 
number of breast cancers in the US AIDS population (men and women).6 HIV-positive breast cancer 
patients have also been documented in South Africa,
7-9
 including within a 2007-2011 breast cancer 
case series in Soweto’s Chris Hani Baragwanath Academic Hospital which included 151 women co-
affected by HIV and breast cancer.
7
 The HIV-positive breast cancer patient population is expected to 
further increase in absolute size over the coming decades, assuming that access to HAART continues. 
It is thus timely to build the epidemiologic evidence base for breast cancer in WLWHA. Pertinent 
issues are diverse10 and have begun to be addressed,11,12 ranging from breast cancer awareness and 
early breast cancer detection in WLWHA, to clinical co-management of two diseases. The need for 
research on these issues will in part depend on the number of WLWHA affected by breast cancer. In 
the present study, amongst the 16 million WLWHA aged 15 years and over, we provide the first 
global estimates of the number of HIV-positive women who were newly diagnosed with breast cancer 
in 2012. We also examine their age and geographical distribution worldwide, and identify the settings 
where HIV-positive breast cancer patients constitute a substantial proportion of the breast cancer 
patient profile.  Finally, a systematic literature review was conducted to assess the consistency of our 
estimates with published reports of HIV-positive breast cancer patients. 
 
Methods 
Breast cancers in WLWHA 
We estimated the number of new breast cancers occurring in WLWHA aged 15 years and over in 
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2012, overall, by age, and UN sub-region. The basis of the primary estimation, which will be 
considered later, was to assume that there was no direct or indirect association between HIV and breast 
cancer risk, thus the number of HIV-positive breast cancers was calculated as the total number of 
breast cancers multiplied by the corresponding HIV prevalence in a given age-country stratum.   
 
For each country, age-specific breast cancer incidence (number of new cases) in 2012 was sourced 
from IARC GLOBOCAN.
13
 They were available for 184 countries or territories and in 5-year age 
bands: 15-19, 20-24, … , 70-74, and 75+ years. These estimates are of variable quality depending on 
the country, ranging from high quality cancer registries included in Cancer Incidence in Five 
Continents (CI5) with national, regional or low (<10%) coverage, to lower quality national rates, 
regional rates or frequency data. The methods for generating the GLOBOCAN estimates include either 
projections of most recently available incidence rates to the 2012 population, modelling of mortality, 
survival or mortality:incidence ratios, or weighted averages of local rates or of neighbouring countries’ 
estimates.13  For 158 of the 184 countries, corresponding age-specific HIV prevalence estimates for 
females were obtained from UNAIDS, which were estimated for a similar period, in 2013. For 
simplicity, from here on we refer to all derived combined estimates as for the year 2012. The estimates 
published by UNAIDS incorporate multiple sources of prevalence data (e.g. HIV prevalence surveys 
among the general population, prevalence among pregnant women, surveys among populations at 
increased risk of HIV), programmatic data as well as modelling assumptions. The latter depended on 
the type of HIV epidemic in a country, i.e. whether it was a generalized population epidemic (e.g. in 
most of sub-Saharan Africa), an epidemic concentrated in intravenous drug users (e.g. Eastern Europe 
and Central Asia) or if it was concentrated in other high risk populations (e.g. Asia or Latin 
America).
14
 The modelled estimates of people living with HIV aged over 50 years were further 
validated against survey data. The 27 countries that did not have HIV prevalence data are listed in 
Supplementary Table 1; they are expected to have small HIV-positive populations, thus their omission 
here should be inconsequential.  
 
To estimate HIV-positive breast cancers, the primary method assumed no association, either direct or 
indirect, between HIV and breast cancer risk for a given country and age stratum. This assumption was 
made because breast cancer is not a HIV-associated cancer; several studies in HIV-endemic areas have 
shown that the HIV prevalence among breast cancer patients is similar to that of the age-matched 
source population.
7-9
  However, US investigations have shown a deficit of breast cancer in WLWAH, 
which could not be explained by potential differences in reproductive or other lifestyle factors. Most 
notably, incidence in the US HIV/AIDS Cancer Match study suggests a 42% breast cancer deficit in 
the US HIV-positive population.15 Based on these latter observations, we also provide a lower 
worldwide estimate. 
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Literature review 
To assess the degree of consistency of the present estimates with the previous literature, we 
systematically reviewed studies that have documented the occurrence of breast cancer in HIV-positive 
women either as part of breast cancer case series or breast cancers occurring in HIV cohorts. The 
review search identified articles containing the terms “cancer” and “HIV”, through a literature search 
conducted with the US National Library of Medicine PubMed on 18
th
 October 2017, and, so as to be 
relevant to the HAART era, it was restricted to articles published in English after 1st January 2000. 
This search yielded 760 results after excluding reviews and commentaries. These 760 publications 
were screened and deemed eligible if they reported on at least five HIV-positive women with breast 
cancer.  
 
Statistical analysis 
The GATHER checklist was followed for these global estimates (Supplementary Table 2). The 
primary estimates of breast cancers in WLWHA assume no association between HIV and breast 
cancer risk. In a given country i (i=1, . . ., 184 for all countries worldwide) and age group j (j=15-
19,20-24, 25-29, … 70-74, 75+ years), we estimated the number of breast cancers in WLWHA (yij) as 
the number of incident breast cancers in women in that country-age stratum nij multiplied by the HIV 
prevalence proportion (pij) in that stratum: yij = nij pij. Breast cancers in WLWHA are presented by 
aggregating over age group j and UN world sub-regions16 and based on these aggregate estimates, the 
proportion of all breast cancer patients who are HIV-positive was calculated as yi./ni. All analyses and 
graphics were performed in STATA version 14.0. In the presentation of results, sub-regional estimates 
are provided but not country-specific estimates, in line with conditions of use of the UNAIDS data.  
 
We also considered the impact of uncertainties in the estimates of WLWHA and in the breast cancer - 
HIV association. For the former, uncertainty in the number of WLWHA at older ages is relatively 
small, of the order of  ±5%1, and for the latter, a 42% deficit of breast cancer found in the US HIV 
population
15
. We therefore also estimated a lower bound on the number of breast cancers in WLWHA, 
by multiplying estimates by (1-0.05)(1-0.42). An upper bound was not calculated because there is no 
suggestion of an excess of breast cancer in WLWHA.  
 
Results 
Global estimates of breast cancer in WLWHA 
In 2012 worldwide, there were an estimated 16.0 million WLWHA worldwide (aged 15+ years). The 
highest HIV-prevalence proportions were in sub-Saharan Africa, which had 12.8 million (80%) of all 
WLWHA. At ages 15+ years, Southern Africa had the highest HIV prevalence (20.0%, 4.1 million 
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WLWHA). Despite much lower HIV prevalence of 5.4% in Eastern Africa (5.5 million WLWHA) and 
2.5% in Western Africa (2.3 million WLWHA), these sub-regions also have large WLWHA 
populations. Other sub-regions had low (<1%) HIV prevalence, but WLWHA populations were still 
substantial in size in North America (0.28 million), South America (0.37), Eastern Europe (0.39), 
South Eastern Asia (0.62) and South Central Asia (0.8). Most WLWHA over age 15 in each sub-
region were young, with only 5.0 million WLWHA (31%) aged 40+ years. Breast cancer ranked 
amongst the top three cancers in women in all sub-regions (Figure 1). 
  
The age-structure of the WLWHA population and corresponding age-specific breast cancer incidence 
rates are shown in Figure 2, for eight sub-regions were there were at least 100,000 WLWHA over age 
15 years, and all other sub-regions combined. The overall pattern is one of relatively low breast cancer 
incidence rates in regions with large populations of WLWHA. For example, in Eastern Africa, the sub-
region with most WLWHA, breast cancer incidence rates were relatively low compared to world 
averages, giving an estimated 1563 breast cancers in HIV-positive women. Because breast cancer 
incidence rates were higher in Southern Africa and, at older ages, in Western Africa, those two sub-
regions had nearly as many HIV-positive breast cancers as Eastern Africa despite fewer WLWHA 
(Figure 3, Supplementary Table 3).  Outside of sub-Saharan Africa, breast cancer incidence rates were 
high at old ages (>60 years) in certain sub-regions, e.g. Northern America and Europe, but these 
population groups have small populations of WLWHA. Consequently, an estimated 6325 breast 
cancers occurred in WLWHA in 2012 worldwide (Supplementary Table 3), of which 75% were in 
sub-Saharan Africa, and outside this sub-region, Northern America, South Central Asia and South 
America also each had over 200 such women. Under the scenario of a breast cancer deficit, total 
number of breast cancers in WLWHA worldwide would reduce from 6325 to 3610 (not considered 
further). 
 
The majority (70%) of HIV-positive breast cancers were diagnosed below age 50, most at 35-49 years, 
whilst in North America only 43% occurred at these ages (Figure 3), which reflects the younger age 
structure of the HIV-positive population.  The proportion of breast cancer patients who were HIV-
positive – a key indicator for health planning and resource allocation – is shown, by sub-region and 
age, in Figure 4. These proportions are very low (<1%) in every sub-region, except, under age 50 in 
the Caribbean (1%), in Middle, Western and Eastern Africa (4-6%), and Southern Africa (26%), and, 
over age 50, in Eastern (3.2%) and Southern Africa (7.6%). 
 
Literature review 
Table 1 lists published studies worldwide that have documented the occurrence of breast cancer in at 
least five HIV-positive women.  Unsurprisingly, most studies originated from sub-Saharan Africa and 
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the US, i.e. locations with considerable patient populations and/or research infrastructure. In these 
publications, amongst breast cancer series the range of HIV-prevalence in Southern (11% to 32%), 
Eastern (11 to 14%) and Western Africa (≤5%) are in line with our estimates, whilst elsewhere the low 
HIV prevalence in unselected breast cancer patients required study designs other than breast cancer 
case series, i.e. mostly HIV cohorts. Mean/median age at breast cancer diagnosis amongst those who 
were HIV-positive ranged from 37 to 48 years in all studies with the exception of a US study of 43 
women (median 53 years). HIV-positive breast cancer patients were diagnosed at younger ages than 
their HIV-negative counterparts, in line with our global estimates.    
 
Discussion 
Using country-level estimates of HIV prevalence and breast cancer incidence from UNAIDS and 
IARC-GLOBOCAN respectively, we estimated the worldwide burden of new breast cancers in 
WLWHA to be 6300 in 2012, 75% of which occurred in Southern, Eastern and Western Africa.  
Because the HIV-positive population has a young age structure, 75% of this patient population was 
diagnosed at ages 35-54 years. Although Southern Africa has a smaller population of WLWHA than 
Eastern Africa, the two sub-regions each had one-quarter of patients due to higher breast cancer 
incidence rates in the latter sub-region.  Under the scenario that a deficit of breast cancer occurs in 
WLWHA, as has been observed in the US, the worldwide burden would be nearer 3600.  
 
The size of this patient population is already appreciable in absolute terms. Ranking countries 
worldwide by the number of incident breast cancers in 2012, the WLWHA population would rank 38
th
 
out of 184 countries (i.e. 80th percentile), with a total breast cancer incidence similar to that of Sweden.  
In comparison with the AIDS defining malignancy, Kaposi Sarcoma (KS), for every 5 women with 
KS, there were an estimated 2 breast cancers in WLWHA.17 Further, this absolute incidence burden is 
expected to increase in size over the next 1-2 decades, owing to ageing of the current HIV population 
and to an additional 1 million women newly diagnosed with HIV each year. However, we deliberately 
did not attempt to predict the future burden, because of the uncertainties around several parameters, 
including continued access to HAART and the breast cancer risk factor profile of the young HIV-
positive population.  
 
These global estimates of the HIV-positive breast cancer patient population are subject to an 
assumption of no HIV-breast cancer risk association. This assumption is supported by three sub-
Saharan African studies, where the HIV prevalence among breast cancer patients was similar to that of 
the age-matched source population.
7-9
  These studies were conducted in South Africa, and included 
patients diagnosed both in the pre-HAART9 and post-HAART era7,8. Lending further plausibility to 
this assumption, for a given setting, our estimated HIV-prevalence among breast cancer patients was 
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consistent with the published studies from that sub-region, as reviewed. Together, these suggest that 
the deficit of breast cancer in HIV+ women in the US may not be a universal feature of WLWHA. 
However, further studies on the HIV-breast cancer risk link in HIV endemic areas are needed, as few 
have been able to examine how incidence is affected by HIV directly or through indirect pathways, 
e.g. due to altered distributions of breast cancer risk factors such as parity, age at first birth and breast 
feeding. The US results may also differ to African findings as the former are set within populations 
regularly screened for breast cancer, some of which are over-diagnoses, whereas in most HIV endemic 
sub-regions almost all breast cancer patients are diagnosed at symptomatic stages.   
 
The estimates are also limited by uncertainties in HIV prevalence data and, especially, in breast cancer 
incidence data. GLOBOCAN estimates have larger uncertainties in some HIV-endemic countries in 
sub-Saharan Africa as the region has few population-based or other cancer registries. Notably, of 54 
African countries/territories listed in GLOBOCAN, only seven had high-quality data (four in North 
Africa and three in countries with a high HIV prevalence). The large populations of Nigeria, South 
Africa and Ethiopia had lower quality national cancer incidence data, and in twenty, mostly smaller, 
countries data from neighbouring countries were used to generate national cancer incidence estimates. 
Nevertheless, the GLOBOCAN estimates are well-recognized as the most accurate data-driven 
estimates currently available.    
 
An opportunity and need exists to improve outcomes for HIV-positive breast cancer patients facing 
two chronic diseases. Where the majority of this patient population lies, in sub-Saharan Africa, breast 
cancer is typified by an advanced stage distribution at diagnosis and poor survival.18 Prolonged 
intervals to diagnosis are a major contributor to late stage,
19
 but for WLWHA, their established contact 
with the health system for HAART medication offers an opportunity to educate about breast and other 
cancers, to encourage early presentation, and ensure referral, diagnosis and treatment not only of 
AIDS-associated malignancies, but also of other common cancers. Similar to the integration of 
cervical cancer screening into HIV clinics,20 this contact provides a valuable opportunity for breast 
health awareness, education and early presentation in order to minimize delays to diagnosis, achieve 
early stage diagnosis and ultimately improve survival, should breast cancer arise. Examples of such 
programs include the Swaziland Breast and Cervix Cancer Network and the Tanzania Health 
Promotion Support group’s program, which provide HIV testing, cervical inspection by visual 
inspection with acetic acid (VIA) and referrals for suspected breast cancer via a mobile clinic. 
However, in the context of the younger patient and the sub-Saharan African setting, benign breast 
disease, tuberculosis and, occasionally, Kaposi sarcoma of the breast add to diagnostic challenges. 
Turning to higher-income countries, attendance of breast cancer screening amongst WLWHA was 
higher than that of the general population in France,
21
 but lower in Ontario, Canada,
22
 thus a setting-
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specific evaluation of early-diagnosis interventions needed in WLWHA is warranted.   
 
In the sub-Saharan African region, where 75% of HIV-positive breast cancer patients live, breast 
cancer survival rates are generally some of the lowest worldwide.  For HIV-positive and HIV-negative 
women combined, 5-year breast cancer survival estimates are 24% in Nigeria, 46% in Ethiopia, and 
64%/80% in black/white South Africans,23-26 which compare to over 85% in the US.27 Moreover, HIV-
positive breast cancer patients have lower survival than their setting-matched HIV-negative 
counterparts. A study in the US  revealed excess all-cause mortality in HIV-positive breast cancer 
patients relative to women with only one of the two diseases.
28
 Moving to sub-Saharan Africa, there 
are two relevant survival studies. In the Uganda Cancer Cohort, 24 HIV-positive women with breast 
cancer had 2-fold increased mortality rates (hazard ratio 2.04; 95% CI 0.76, 5.47) compared to HIV-
negative breast cancer women,29 whilst in 88 HIV-positive breast cancer patients in Soweto, a non-
significant increased mortality rate was seen (hazard ratio 1.4) relative to their HIV-negative 
counterparts.30 In addition to further survival studies, research needs to address side-effects and 
survivorship, with relevant studies currently underway
12,19
. Clinically, concerns have been raised 
related to delays in initiating primary or adjuvant chemotherapy in highly immuno-suppressed 
patients, HAART-chemotherapy interactions, and a higher incidence of intolerance to, and side-effects 
of, chemotherapy, including chemotherapy-induced neutropenia31, which are often exacerbated in the 
HIV-positive cancer patient.
3
 In palliative care patients in South Africa and Uganda, Selman et al. 
found lower quality of life in HIV-positive patients than in cancer patients, and lack of psychosocial 
support mechanisms for the small proportion of women with both diagnoses.
32
  Some countries such 
as Uganda have prioritized palliative care for HIV and cancer patients.  
 
In conclusion, the estimated 6300 new breast cancer patients diagnosed in 2012 amongst women 
living with HIV is substantial. Research that addresses the impact of these combined comorbidities 
along the entire patient journey for both diseases is warranted in the settings we identified here. 
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Table 1: Reports published since 2000 of at least 5 HIV-positive women with breast cancer, in (A) 
studies of breast cancer or of all cancer types, and (B) HIV cohorts.  
 
Continent, sub-region 
Country, location/study, First author 
(sorted by sub-region alphabetically and by 
decreasing no. of HIV-positive breast cancers) 
Year of 
breast cancer 
diagnosis 
No. of women in 
breast cancer series 
(A) or in cohort (B) 
No. HIV-positive 
women with breast 
cancer 
 (% of all breast 
cancers) 
Median/mean 
age at breast 
cancer diagnosis 
in WLWHA; all 
A. Cancer or breast cancer focused studies (case series/case-control studies) 
Africa, Eastern Africa 
 Uganda, ABC-DO, McKenzie
19
 
 Zambia, ABC-DO, McKenzie
19
 
 Uganda, Coghill
29
 
 
2014-17 
2014-17 
2003-10 
 
439 
251 
220 
 
49 (11) 
36 (14) 
24 (11) 
 
45; 48 
45; 50 
- 
Africa, Southern Africa 
 S. Africa, Soweto, Cubasch7 
 Namibia, Windhoek, McKenzie
19
 
S. Africa, Johannesburg, Sitas
9
 
 S. Africa, Pretoria, Phakathi8 
 S. Africa, Cape Town, Langenhoven33 
 S. Africa, Durban, Ngidi
31
 
 
2006-12 
2014-17 
1995-99 
2009-14 
2010-11 
2012-15 
 
1092 
503 
687 
161 
586 
65 
 
151 (14) 
56 (11) 
43 (6) 
31 (19) 
31 (5 to 7) 
21 (32) 
 
44; 55 
47; 54 
- 
- 
42; 56 
41; 49 
Africa, Western Africa  
 Guinea, Conakry
34
 
 Nigeria, Aba/Owerri, McKenzie19 
 Benin, Ivory Coast, Niger, Togo, Jaquet35 
 
2007-12 
2014-17 
2009-12 
 
278 
462 
294 
 
14 (5) 
11 (3) 
17 (6) 
 
37; 49 
43; 46 
- 
America, Northern America 
 US, New York, Parameswaran
36
 
 US, Miami Jackson Memorial Hosp. Gomez
4,37
 
 US, Baltimore-Washington, Presti
38
 
 US, Harlem, Oluwole39 
 
1996-2011 
1989-2013 
2004-14 
1995-2008 
 
* 
* 
3012 
600 
 
52 (*) 
47 (*) 
43 (1) 
11 (2) 
 
- 
46; - 
53; 60 
- 
B. HIV-focused studies (predominantly cohorts) 
Africa, Eastern Africa 
Uganda, Kyadondo county, Mbulaiteye
40
 
 
1989-2002 
 
8423* 
 
15 
 
- 
Africa, Western Africa 
 Nigeria, Abuja, Akarolo-Anthony
41
 
 
2009-12 
 
10580 (8/8) 
 
16 
 
- 
America, Northern America 
 US, HIV Cancer Match Study, Shiels6 
AIDS 
       AIDS 
       HIV 
 US, Connecticut, Michigan, Texas, Suneja
42
 
 US, WIHS, HERS HIV cohorts, Hessol
43
 
 US, Maryland, Singh
44
 
 US, New Orleans, Ruiz
45
 
 Canada, British Columbia, Chiu46 
 
2001-05 
2004-07 
2004-07 
1996-2010 
- 
2000-10 
2002-10 
1996-2008 
 
419137 py 
276702 py 
284504 py 
NA 
NA 
NA 
699 
902 
 
337 
203 
166 
108 
23 
17 
5 
5 
 
- 
- 
- 
- 
46;- 
48; 55 
46 
- 
America, South America 
 Brazil, Rio de Janeiro, Andrade47 
 
1996-2009 
 
860 
 
9 
 
46 
Europe 
 France, ONCOVIH study, Spano,
5
 Lanoy
48
 
 Italy, Brescia  Calabresi
49
 
 Italy, MASTER cohort, Gotti50 
 
2006 
1999-2009 
1998-2012 
 
~93100** 
5253** 
13388** 
 
19 
9 
30 
 
44 
42 
42 
Southern Asia 
 India, Pune, Godbole51 
 
1996-2008 
 
- 
 
68 (23 prevalent) 
 
- 
Eastern Asia 
 China, Beijing, Yang
52
 
 
2008-13 
 
399 
 
6 
 
- 
* Design factor: percentage not provided if this was a fixed factor by design; NA – not provided in the original publication 
or not relevant; **men and women; py=woman-years; 
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Figure Legends  
 
Figure 1: Rank of breast cancer amongst new cancers in all women, by country, 2012. Source: IARC 
Globocan 
 
Figure 2: Sub-region-specific age distribution of WLWHA and corresponding age-specific breast 
cancer incidence rates in 2012 (equivalent worldwide rates are also shown for comparison). Regions 
with over 100,000 WLWHA over age 15 are shown, and the remaining sub-regions are combined in 
‘other’ (Western, Northern and Southern Europe, Northern Africa, Central America, Western Asia, 
Melanesia, Polynesia, Micronesia and Australia/New Zealand). 
 
Figure 3: A. Total and age-specific number of women age 15+ years living with HIV/AIDS, by UN 
sub-region.  B. Estimated number of breast cancers in women living with HIV/AIDS in 2012, by UN 
sub-region.  
 
Figure 4: Age-specific percentage of newly diagnosed breast cancer patients who are HIV-positive, 
by UN sub-region. 
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Figure 1: Rank of breast cancer amongst new cancers in all women, by country, 2012. Source: IARC 
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